Disruption of NANOG-driven epithelial-mesenchymal transition (EMT) and self-renewal restores drug sensitivity in colorectal cancer
NANOG drives CRC-SC maintenance via ERK/GSK-3β/β-catenin signalling and EMT modulation. This study offers significant insights into the translational impact of targeting NANOG and its downstream pathways with small-molecule inhibitors U0126 and TDZD-8 and presents a promising strategy to reduce CRC-SCs stemness, functionality, and tumourigenicity.
Authors
- Amirreza Mazloomi
- Chris Denning (ORCID: https://orcid.org/0000-0003-0802-8617)
- Dominique A. Bonnet (ORCID: https://orcid.org/0000-0002-4735-5226)
- Roya Babaei‐Jadidi (ORCID: https://orcid.org/0009-0007-5001-3124)
- Sameerah Shaheen (ORCID: https://orcid.org/0000-0003-0646-1847)
- Mehreen Ahmed (ORCID: https://orcid.org/0000-0002-0422-2343)
- Kiarash Saleki (ORCID: https://orcid.org/0000-0003-4159-7299)
- Bradley Spencer‐Dene (ORCID: https://orcid.org/0000-0001-9533-5839)
- Abdolrahman S. Nateri (ORCID: https://orcid.org/0000-0002-6422-6813)
- Hossein Kashfi
- Miao Xue (ORCID: https://orcid.org/0000-0002-2040-6492)
- Sepideh Youssefi
Institutions
- University of Nottingham (GB)
- The Francis Crick Institute (GB)
- Moffitt Cancer Center (US)
- London Cancer (GB)
Publication Details
- Journal
- Drug Resistance Updates
- Published
- 2025-11-05
- DOI
- https://doi.org/10.1016/j.drup.2025.101321
- Citations
- 3
- Primary Topic
- Cancer Cells and Metastasis
- Type
- article
- Field-Weighted Citation Impact
- 3.14